<DOC>
	<DOC>NCT01441973</DOC>
	<brief_summary>The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56^dim cells (a marker for the health of the body's immune system)</brief_summary>
	<brief_title>Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma</brief_title>
	<detailed_description>Intervention model: Dosing is sequential</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Key Participants with a confirmed diagnosis, according to criteria of the International Myeloma Working Group, of smoldering multiple myeloma, considered high risk according to the following: Serum monoclonal (M) protein ≥3 gm/dL and bone marrow plasma cells (BMPC) ≥10% or Serum M protein 13 g/dL and BMPC ≥10% and abnormal free light chain ratio of &lt;0.125 or &gt;8.0 Urine M protein &gt;200 mg/24 hours, ≥10% BMPC, and serum free light chain ratio ≤0.125 or ≥8.0 Key Active multiple myeloma Monoclonal gammopathy of undetermined significance Active plasma cell leukemia Positive for hepatitis B or C virus or HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>